Prostate Cancer Risk Calculator
Introduction: what a PSA number can and cannot tell you
Prostate-specific antigen is produced by prostate tissue, not by prostate cancer specifically. That single fact explains most of the confusion around PSA screening. A raised value means the prostate is releasing more protein into the bloodstream than expected, and cancer is only one of several reasons that happens. Benign enlargement, inflammation, infection, recent instrumentation, and even a long bike ride all push the number up.
The consequence is that PSA on its own is a weak discriminator, and the whole art of interpreting it lies in the adjustments: comparing it to what is normal for a man of that age, dividing it by the size of the gland producing it, watching how fast it moves, and looking at what fraction of it circulates unbound.
This page computes those four adjustments and reports each one against its published threshold. What it deliberately does not do is combine them into a single invented probability. A trustworthy percentage requires coefficients fitted to a large biopsy cohort with known outcomes, and coefficients that merely look plausible produce numbers that are both alarming and wrong. The one probability shown here comes straight from the study that measured it, quoted only within the range that study covered.
Nothing on this page is a diagnosis, and no combination of these numbers can rule cancer in or out. Their purpose is to give you a structured, sourced way to prepare for a conversation with a clinician.
How to use the PSA risk assessment calculator
Only age and total PSA are required. Every other field unlocks an additional indicator, and the result tells you which ones it could and could not compute.
- Age and total PSA give the age-specific reference range check, which is available for every user.
- Prostate volume in cubic centimetres unlocks PSA density. You will only have this if you have had a transrectal ultrasound or a prostate MRI; the report usually states it directly.
- Percent free PSA unlocks the published probability table. Ask the laboratory for a free-and-total PSA panel; some report the ratio directly, others report free PSA in ng/mL, in which case divide by the total and multiply by 100.
- A previous PSA and the months since unlock PSA velocity. Use readings from the same laboratory and the same assay wherever possible, because inter-assay differences can exceed the change you are trying to measure.
- Family history is reported qualitatively rather than numerically, because this page does not assign it a fitted coefficient.
The chart underneath plots your PSA against the age-specific band for every age decade, so you can see where the result sits and how the threshold would move as you get older. A shareable link reproduces the whole assessment.
Formula for each of the four PSA adjustments
PSA density normalises the reading by the volume of tissue producing it. With total PSA in ng/mL and prostate volume in cubic centimetres:
A density of ng/mL per cc or above is the threshold most commonly cited in favour of biopsy. The logic is that benign enlargement rarely lifts density that far: a 60 cc gland with a PSA of 6.0 has a density of 0.10 and is plausibly just large, whereas a 25 cc gland with the same PSA has a density of 0.24 and is producing far more antigen than its size explains.
PSA velocity measures the rate of change rather than the level. With a prior reading taken months ago:
giving ng/mL per year, against a classic threshold of ng/mL per year. The caveat is severe: PSA is noisy between draws, so a velocity computed from two points is mostly measuring that noise.
Percent free PSA is the fraction circulating unbound to serum proteins:
Cancer-associated PSA is more often bound, so a lower free fraction points toward malignancy. Catalona and colleagues measured this directly in men with a total PSA between 4.0 and 10.0 ng/mL and a normal digital rectal examination, and published the probability of finding cancer on biopsy for each band of percent free PSA. Those are measured frequencies from a real cohort, not model output, which is why this page quotes them and only inside that PSA window.
The age-specific reference range is not a formula but a lookup, based on the 95th percentile of PSA in healthy men of each decade. Prostate volume grows with age, so the upper limit of normal grows with it.
Reference thresholds used on this page
| Age band | Upper limit of normal (ng/mL) | Effect of using it instead of a flat 4.0 |
|---|---|---|
| 40–49 | 2.5 | Catches cancers in younger men that a flat 4.0 would miss |
| 50–59 | 3.5 | Moderately more sensitive than a flat threshold |
| 60–69 | 4.5 | Slightly more permissive; reduces referrals for benign enlargement |
| 70–79 | 6.5 | Substantially fewer biopsies for age-related enlargement |
| Percent free PSA | Probability of cancer on biopsy | Interpretation |
|---|---|---|
| 0–10% | 56% | High; biopsy usually recommended |
| 10–15% | 28% | Intermediate |
| 15–20% | 20% | Intermediate |
| 20–25% | 16% | Lower |
| Above 25% | 8% | Low; often supports deferring biopsy |
Notice that even the lowest band is 8%, not zero. A reassuring free-PSA ratio lowers the odds; it does not eliminate them.
Worked example: a 62-year-old with a PSA of 6.2
Take a man aged 62 whose total PSA comes back at 6.2 ng/mL. An MRI two months earlier put his prostate volume at 52 cc. His free PSA fraction is 19%, and a reading eighteen months ago was 4.9 ng/mL. He has no family history.
Age-specific range. At 62 the upper limit of normal is 4.5 ng/mL, so 6.2 is above it. Under the older flat 4.0 threshold it would also be flagged, but by a wider apparent margin.
PSA density. His gland is large, which changes the picture:
which is below the 0.15 threshold. A 52 cc prostate is roughly twice the size of a young man's, and a gland that large producing 6.2 ng/mL is not out of proportion to itself.
PSA velocity. The rise from 4.9 to 6.2 over eighteen months gives:
which is above the 0.75 threshold, though only just, and it rests on two measurements that could easily differ by that much for benign reasons.
Free PSA. His total PSA of 6.2 falls inside the 4.0 to 10.0 window the Catalona table covers, and 19% free places him in the 15 to 20% band, giving a published probability of cancer on biopsy of 20%. That is the only genuine probability in this assessment, and it comes with the study's conditions attached: aged 50 to 75, normal digital rectal exam, total PSA in that window.
Three of four indicators are reassuring or borderline; one is mildly adverse. That mixed picture is the normal outcome, and it is exactly why a single number would be misleading. The reasonable next step is a discussion about whether to repeat the PSA before doing anything invasive, which is a very different conversation from one prompted by a fabricated "71% chance of cancer".
Reading the result without over-reading it
Treat the indicators as a set of independent checks rather than a score to be summed. Each was derived from a different cohort under different conditions, and they were never validated as a combined instrument. Two flags do not mean twice the risk.
The two adjustments that carry the most weight in current practice are density and free PSA, because both correct for the dominant confounder, benign enlargement. Velocity has fallen out of favour as evidence accumulated that measurement noise swamps the signal over short intervals. The age-specific range is best thought of as a referral filter rather than a diagnostic line.
If you want a genuine multivariable risk estimate, the validated tools to ask a clinician about are the Prostate Biopsy Collaborative Group calculator and the ERSPC risk calculator, both of which are fitted to large biopsy cohorts and report separate probabilities for any cancer and for clinically significant, high-grade cancer. That last distinction matters more than the headline number: much of the harm in prostate screening comes from detecting and treating cancers that would never have caused symptoms.
Limitations and assumptions you should hold onto
This page is an educational decision aid. Its limitations are substantial and worth stating plainly.
- It is not a diagnosis and not medical advice. No PSA-based calculation can establish or exclude prostate cancer. Only tissue can.
- The indicators are not combined. They come from different studies and populations and were never validated as a joint score, so this page reports them separately and refuses to average them.
- The free-PSA probabilities apply to a narrow population. Men aged 50 to 75, total PSA between 4.0 and 10.0 ng/mL, and a normal digital rectal exam. Outside that window the table is not applicable, and the calculator says so rather than extrapolating.
- Ancestry is a real risk factor that is not modelled. Men of African ancestry have substantially higher incidence and mortality, and several guidelines suggest starting screening discussions earlier. No number here reflects that.
- Medication changes the input. 5-alpha reductase inhibitors such as finasteride and dutasteride roughly halve measured PSA. A value taken while on one of those should be doubled before comparison with any threshold on this page.
- Transient causes are common. Prostatitis, urinary infection, retention, recent catheterisation, recent biopsy, and vigorous cycling all raise PSA temporarily. A single elevated reading is frequently repeated before any action is taken, precisely for this reason.
- Assay differences matter. PSA results are not perfectly interchangeable between laboratories or platforms, which is a particular problem for velocity calculated across different providers.
- Grade is not addressed. None of these indicators distinguishes an indolent cancer from an aggressive one, and that distinction determines whether detection helps or harms.
Sources. Every threshold and probability on this page is taken from published work rather than fitted here, and the arithmetic is shown in full above.
- Age-specific PSA reference ranges (95th percentile: 2.5, 3.5, 4.5, 6.5 ng/mL for the four decades from 40): Oesterling and colleagues, "Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges", JAMA 1993.
- Probability of cancer on biopsy by percent free PSA: Catalona and colleagues, "Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease", JAMA 1998, for men aged 50 to 75 with total PSA 4.0 to 10.0 ng/mL and a normal digital rectal exam.
- PSA density threshold of 0.15 ng/mL per cc and PSA velocity threshold of 0.75 ng/mL per year are long-standing clinical conventions from the urological literature and are used here as reference points, not as decision rules.
- For a validated multivariable estimate, see the Prostate Biopsy Collaborative Group risk calculator, which reports separate probabilities for any cancer and for high-grade cancer.
Questions men ask about PSA results
Why does this page not output a single percentage risk of cancer?
Because a trustworthy single percentage requires coefficients fitted to a large biopsy cohort, and inventing plausible-looking coefficients produces numbers that are alarming and wrong. This page instead reports four separately published indicators, each with the population and conditions it was derived from. The one probability it does show, from the free-PSA table, is quoted directly from the study that measured it and only within the range that study covered.
What is PSA density and why is 0.15 the usual cut-off?
PSA density is total PSA divided by prostate volume in cubic centimetres, which corrects for the fact that a larger gland produces more PSA without any cancer being present. A density of 0.15 ng/mL per cc or above is the threshold most commonly used to argue in favour of biopsy, because benign enlargement rarely pushes density that high. It requires an imaging measurement of gland volume, usually from transrectal ultrasound or MRI.
Is a PSA of 4.0 the line between normal and abnormal?
Not really. The single 4.0 threshold was a historical convention and it both misses cancers in younger men and over-refers older men with benign enlargement. Age-specific reference ranges published by Oesterling and colleagues set the 95th percentile at 2.5 for ages 40 to 49, 3.5 for 50 to 59, 4.5 for 60 to 69, and 6.5 for 70 to 79 ng/mL, which raises sensitivity in younger men and specificity in older ones.
How reliable is PSA velocity?
Less than it once appeared. A rise faster than 0.75 ng/mL per year is the classic threshold, but PSA fluctuates substantially between draws for reasons unrelated to cancer, including infection, recent ejaculation, cycling, and laboratory assay differences. Velocity calculated from only two measurements is dominated by that noise, so at least three readings over 18 to 24 months, all from the same assay, are needed before the number means much.
What raises PSA other than cancer?
Benign prostatic hyperplasia is the most common cause, along with prostatitis, urinary tract infection, urinary retention, recent catheterisation, prostate biopsy, and vigorous cycling. In the opposite direction, 5-alpha reductase inhibitors such as finasteride and dutasteride roughly halve measured PSA, so a value from a man taking one of those should be doubled before it is compared with any reference range.
Should I be screened for prostate cancer at all?
That is a decision to make with a clinician, not a calculator. Major guidelines describe PSA screening as a shared decision rather than a routine recommendation, because it reduces prostate cancer mortality modestly while also detecting cancers that would never have caused harm. Family history, ancestry, and your own tolerance for the consequences of a positive result all belong in that conversation.
Status messages will appear here.
Arcade Mini-Game: Prostate Cancer Risk Calculator Calibration Run
Use this quick arcade run to practice separating useful scenario inputs from common planning mistakes before you rely on the calculator output.
Start the game, then use your pointer or arrow keys to catch useful inputs and avoid bad assumptions.